Annexon Inc. (ANNX) is threading together a trio of late-stage programs that could reshape treatment options across neurology, ophthalmology, and autoimmunity. With global filings, pivotal data, and mechanistic innovation converging through 2026, the company is building momentum around a single molecular target, C1q, and translating it into three distinct therapeutic strategies.
Tanruprubart for Guillain-Barré Syndrome: Regulatory Engagement Underway
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com